Live from AACR Annual Meeting 2019: Monday -- Clinical Trials Plenary Session 3

• Date :
• 31    
  0

Clinical trials in Africa: Bench to bedside

• Date :
• 4    
  1

Live from AACR Annual Meeting 2019: Tuesday -- Clinical Trials Plenary Session 4

• Date :
• 3    
  0

Live from AACR Annual Meeting 2019: Sunday Afternoon -- Clinical Trials Plenary Session 2

• Date :
• 2    
  0

5' UTR mutations in prostate cancer

• Date :
• 1    
  0

HER2-targeted CAR T-cell therapy safe, with promising antitumor activity

• Date :
• 1    
  1

Evaluation of M7824, a bifunctional fusion protein targeting

• Date :
• 1    
  0

Improving cancer care in Nigeria

• Date :
• 0    
  0

TATTON: Updated results for patients with EGFR-mutant positive NSCLC

• Date :
• 0    
  0

Mesothelin-targeted CAR T-cell therapy safe

• Date :
• 0    
  0

Immune checkpoint inhibitor combination efficacious

• Date :
• 0    
  0

Personalised research for cancer care in Africa

• Date :
• 0    
  0

Inequities in global healthcare

• Date :
• 0    
  0

MYSTIC: Developing biomarkers for metastatic NSCLC

• Date :
• 0    
  0

Trends in breast cancer incidence and risk

• Date :
• 0    
  0

Accelerated tumour growth due to immunotherapy: Fact or fiction?

• Date :
• 0    
  0

Targeting NSCLC patients with brain and liver metastases

• Date :
• 0    
  0

Increased stroke risk in childhood cancer survivors

• Date :
• 0    
  0

Cancer preventive vaccine showed promising results in preclinical model of Lynch syndrome

• Date :
• 0    
  0

Importance of capacity development for African researchers

• Date :
• 0    
  0

Using regionally delivered autologous mesothelin-targeted CAR T

• Date :
• 0    
  0

Osimertinib plus savolitinib for patients with EGFR-mutant

• Date :
• 0    
  0

Biomarkers of systemic inflammation linked to reduced clinical activity

• Date :
• 0    
  0

Cancer preventive vaccine used in mouse model of Lynch syndrome

• Date :
• 0    
  0

ADMIRAL: Gilteritinib as treatment for patients with relapsed or refractory acute myeloid leukaemia

• Date :
• 0    
  0

Gilteritinib improved survival for patients with acute myeloid leukaemia

• Date :
• 0    
  0

Talimogene laherparepvec combined with neoadjuvant chemotherapy

• Date :
• 0    
  0

Pembrolizumab as treatment for advanced SCLC

• Date :
• 0    
  0

Efficacy and immune correlates of the SRA737 plus LDG

• Date :
• 0    
  0

Lymphodepleting chemotherapy in order to safely improve the expansion

• Date :
• 0    
  0

KEYNOTE trials show pembrolizumab benefited patients with advanced small cell lung cancer

• Date :
• 0    
  0

Social media as a tool for scientists

• Date :
• 0    
  0

Using T cell engineering plus triple checkpoint blockade to enhance the efficacy

• Date :
• 0    
  0

The hereditary link between African-Americans and people in Africa and its relationship

• Date :
• 0    
  0

Combining the SLP vaccine with chemo-immunotherapy

• Date :
• 0    
  0

Digitising clinical assessment and using it for evidence-based prediction of outcomes

• Date :
• 0    
  0

African Access Initiative: Improving patient outcomes in Africa

• Date :
• 0    
  0

Umbralisib as a monotherapy in patients with relapsed/refractory marginal zone lymphoma

• Date :
• 0    
  0

Risk factors for prostate cancer in men of African descent

• Date :
• 0    
  0

Umbralisib shows early promise for patients with marginal zone lymphoma

• Date :
• 0    
  0

Congrès ESMO 2026

• Date :
• 807    
  0

Congrès ESMO d'Immuno-Oncologie 2025

• Date :
• 1322    
  0

SABCS 2025 Symposium

• Date :
• 7723    
  0

Congrès ESMO Asie 2025

• Date :
• 952    
  0

17ᵉ Congrès Européen Multidisciplinaire sur le Cancer Urologique - EMUC25

• Date :
• 1417    
  0